Product Images Trintellix

Trintellix is a prescription drug with the active ingredient vortioxetine. The label includes information on the drug's NDC, expiration date, and lot number. The drug was manufactured by Takeda Pharma Am. and repackaged by RemedyRepack Inc. The label warns to keep the medication away from children and store it within a specific temperature range. The package insert should be consulted for directions on usage.*

Trintellix (Vortioxetine) is a prescription drug manufactured by Takeda Pharma Am., Inc., Deerfield, IL 60015. The package insert should be consulted for directions of use. Keep this medication out of reach of children. The drug should be stored at a temperature of 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F) [See USP]. This product has been repackaged by RemedyRepack Inc., Indiana, PA 15701, 724.466.8762. The LOT# and Expiry date are not available.*

This text is describing population data such as age, race, and renal/hepatic impairment status, as well as PK (pharmacokinetic) parameters such as AUC and Cmax, and fold change relative to a reference. Specific values are given for each category listed.*

This is a list of drugs that interact with specific enzymes in the body, including inhibitors for CYP2D6, CYP3A/Pgp, and CYP2C9/2C19/3A, as well as inducers for CVP. The list also includes ethanol and aspirin. The last section appears to contain data in the form of a graph representing fold change and 90% confidence intervals relative to vortioxetine alone, but it is not clear what specifically this refers to without further context.*

This is a list of drugs and their classification as substrates for different types of enzymes. The enzymes include CYP2B6, CYP2C9, CYP2C19, and CYP3A. The drugs listed include Bupropion, (S)Warfarin, Diazepam, Omeprazole, Ethinyl estradiol, Levonorgestrel, (R)-Warfarin, Aspirin, Ethanol, and Lithium. The data also includes PK parameters such as AUC, Cmax, and fold change relative to interacting drug alone.*

This is a list of TRINTELLIX dosage for six different studies, including details about the study location and whether it was a US or non-US study. There is also a graph that shows the difference in effectiveness between TRINTELLIX and placebo.*

The text describes a chart showing the proportion of patients with recurrence over time. Two different treatments, TRINTELLIX (5 or 10 mg) and a placebo, are compared. The chart shows that patients taking TRINTELLIX had a lower proportion of recurrence over time compared to those taking the placebo. The x-axis shows the time to recurrence in weeks, and the y-axis shows the number of patients maintained.*

The text appears to be a chart displaying the time to recurrence in weeks for patients maintained on different doses of TRINTELLIX and placebo. The number of patients maintained and the proportion of patients with recurrence are also included in the chart.*

This is a comparison table between Trintellix and Escitalopram with 10 or 20mg dosages. The table shows the improvement in a study over time (measured in weeks) from the baseline. No further information is available.*

The text is reporting the change from Basel, but the context is not clear. It also mentions the worsening, a placebo, Trintellix at 10mg and 20mg, and Paroxetine at 20mg. No further information is provided for an accurate description.*